• German Patent and Trade Mark Office (GPTO)A one-day, comparative law symposium on "Patent Litigation in Japan and Germany" will be held on October 4, 2018 at the German Patent and Trade Mark Office (GPTO) in Munich, Germany.  Experts on patent litigation proceedings from Japan and Germany will be speaking at the event, providing an overview of the current case law in both countries.  Further, this event will offer a practice-oriented comparison of current legal issues such as claim construction and doctrine of equivalence or the protection of confidential information in patent litigation.  The language of the symposium will be English.

    Additional information regarding the symposium can be found here.  While there is no cost to participate in the program, advance registration is required.  Those interested in attending the webinar can register here.

  • By Kevin E. Noonan —

    Acorda TherapeuticsDetermining obviousness is always a reconstruction, imperfectly done, of a past that never was.  The prior art is consulted and the question asked, would the worker of ordinary skill in the art have been able to achieve the claimed invention with a reasonable expectation of success?  Of course, this question is posed against a backdrop of the ordinarily skilled worker not having achieved the invention; that accomplishment was attained by the named inventor.  Nevertheless, the Supreme Court since Hotchkiss and the Patent Act since 1952 has recognized that sometimes the answer to the question must be no, if only to ensure that the constitutional mandate that Congress only grant patents that will "promote the progress of . . . the useful arts" be satisfied.

    Roxane LaboratoriesIn patent litigation, defendants have the motivation to cast the imperfect past in light most favorable to the claimed invention being obvious, and to balance the rhetorical scales they also bear the burden of establishing obviousness (as in all invalidity pleadings) by clear and convincing evidence.  But what is clear and convincing to some is not to others, and the Federal Circuit's split decision affirming the District Court's obviousness determination in Acorda Therapeutics, Inc. v. Roxane Labs., Inc. illustrates the point — and at the same time shows that even the "objective" indicia of non-obviousness identified by the Supreme Court in Graham v. John Deere do not always provide a reliable, fact-and historically based shield to a finding of non-obviousness.

    The lawsuit arose when Roxane and co-Defendants Mylan Pharmaceuticals, Inc., and Teva Pharmaceuticals USA, Inc. each filed an Abbreviated New Drug Application (ANDA) for Acorda's multiple sclerosis drug (Ampyra®) and sent Paragraph IV letters to Acorda (and co-Plaintiff Alkermes Pharma Ireland Ltd.) asserting that four Orange Book-listed patents (U.S. Patent Nos. 8,007,826; 8,663,685; 8,354,437; and 8,440,703) were invalid.  As the Federal Circuit panel stated, there was one additional patent, U.S. Patent No. 5,540,938, owned by Elan Corp. plc and exclusively licensed to Acorda.  That patent broadly claimed therapeutic formulations of 4-aminopyridine (4-AP); Acorda's patents were for more narrow formulations having specific characteristics and properties that distinguished (undisputedly, for novelty purposes) these claims from the claims of the '938 patent.

    For the purposes of the appeal all the asserted claims recited methods, dosing regimens, and sustained-release formulations for "methods of administering to a patient with multiple sclerosis a sustained-release 4-AP formulation (1) in a 10 mg dose twice daily, (2) at that stable dose for the entire treatment period of at least two weeks, (3) maintaining 4-AP serum levels of 15–35 ng/ml, (4) with walking improved."  The parties treated the following claims as representative:

    Asserted claim 7 (dependent on claim 6) of the '826 patent:

    6.  A dosing regimen method for providing a 4-aminopyridine at a therapeutically effective con- centration in order to improve walking in a human with multiple sclerosis in need thereof, said method comprising:
        initiating administration of 4-aminopyridine by orally administering to said human a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a day without a prior period of 4-aminopyridine titration, and then,
        maintaining administration of 4-aminopyridine by orally administering to said human a sustained release composition of 10 milligrams of 4-aminopyridine twice daily; without a subsequent period of 4-aminopyridine titration,
        whereby an in vivo CmaxSS:CminSS ratio of 1.0 to 3.5 and a CavSS of 15 ng/ml to 35 ng/ml are maintained in the human.

    Wherein asserted dependent claim 7 includes the limitation "whereby an increase in walking speed is obtained in said human."

    Asserted claim 22 of the '437 patent (dependent on claim 18, which in turn is dependent on claim 1):

    1.  A method of increasing walking speed in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks, wherein said 10 milligrams of 4-aminopyridine twice daily are the only doses of 4- aminopyridine administered to said patient during said time period.

    Wherein claim 18 recites that the dosage form is a tablet, and claim 22 recites that the tableted formulation of 4-aminopydirine "exhibit[s] a release profile to obtain a release profile of about CavSS of 15 ng/ml to 35 ng/ml."

    In the ensuing ANDA litigation the Defendants stipulated to infringement but recited as counterclaims that all claims at issue were invalid for obviousness.  The District Court found the '826, '685, '437, and '703 (but not the '938 patent) obvious, and entered final judgment and an injunction that precluded final approval by the FDA of Defendants' ANDAs until July 20, 2018 (the expiration date of the '938 patent).  This appeal ensued.

    Federal Circuit SealThe Federal Circuit affirmed, in an opinion by Judge Taranto joined by Judge Dyk; Judge Newman dissented (vigorously).  The opinion set forth the extensive prior art asserted against Acorda's claims, as well as evidence that Elan had tried (and failed) to produce a suitable 4-AP formulation, and that Sanofi had also attempted making such a formulation without success.  Distinctions with the prior art included the need to titrate the dose of 4-AP, which (as the opinion concedes) had a "narrow toxic-to-therapeutic range[]"; also noted in the opinion was the variable reports of efficacy and frequent reports of serious side effects (including seizures) and that Acorda's methods, administration regimens, and sustained-release formulations were the only ones the FDA approved to improve walking speed in MS patients.

    Nevertheless, the majority affirmed based on finding the salient limitations (set forth above numbered 1-4) recited in the prior art, and that the skilled worker would have had a reasonable expectation of success in achieving the claimed invention in view of this extensive prior art.  The majority rejected Acorda's three contentions:  "that the district court erred in finding that a person of skill would have had a motivation to combine the prior art to arrive at the Acorda invention and a reasonable expectation of success in doing so"; "that the claim limitations relating to pharmacokinetics—i.e., achieving 4-AP serum levels of 15–35 ng/ml— are inherent in the claimed invention and therefore obvious"; and "that the court improperly applied a categorical rule that a blocking patent (the Elan patent) negates any findings in favor of Acorda on the objective indicia of commercial success, failure of others, and long felt but unmet need."  While the majority appears to have cherry-picked the prior art and reconstructed the invention using the claims as a roadmap (illustrating why the Supreme Court might have underestimated the pernicious effects of hindsight in obviousness determinations in KSR Int'l. Co. v. Teleflex. Inc.), it is the majority's rejection of Acorda's third argument that makes this decision noteworthy.

    The majority's consideration of the so-called "secondary considerations" (aka objective indicia of non-obviousness) is grounded in the question of whether the '938 patent is a "blocking patent" that provides the basis for the commercial success of Acorda's Ampyra® drug product.  The commercial success objective indication of non-obviousness is burdened with the requirement that there be a nexus between the success and the claimed invention; it is frequently the case that such assertions are rebutted, inter alia, by a patentee's market power or other alternative explanation for the success.  The majority opinion sets forth the Court's precedent based on rebuttal of an assertion of commercial success as a basis for non-obviousness in Merck & Co. v. Teva Pharmaceuticals USA, Inc., 395 F.3d 1364 (Fed. Cir. 2005), Galderma Laboratories, L.P. v. Tolmar, Inc., 737 F.3d 731 (Fed. Cir. 2013), and Merck Sharp & Dohme Corp. v. Hospira, Inc., 874 F.3d 724 (Fed. Cir. 2017).  In each case, the Court held that the asserted commercial success did not support non-obviousness, due to the existence of another patent, as here not in issue, that explained why others had not marketed a competing product.  Specifically with regard to Merck Sharp & Dohme Corp. v. Hospira, Inc. ("Merck II"), the majority noted that "a blocking patent did not, all by itself, justify discounting evidence of commercial success," calling it a "fact-specific inquiry."  And:

    Merck II's reasoning reflects a common-sense recognition that, as a theoretical matter, a blocking patent may or may not deter innovation in the blocked space by commercially motivated potential innovators other than the owners or licensees of the blocking patent.  Where the owner of the blocking patent or exclusive licensee is different from the owner of the patent in suit, the granting of a license may be a realistic possibility.  Even where, as here, the owner of the patent in suit and the exclusive licensee of the blocking patent are the same, such a potential innovator might or might not think it could successfully challenge the blocking patent.  And such a potential innovator might or might not be willing to research in the blocked space without a license to a blocking patent—even if the research itself is within the safe harbor provided by 35 U.S.C. § 271(e)(1)—and wait until it has already developed and patented its aimed-at improvement to negotiate for a cross-license with the blocking patent's owner to share the profits from the improvement.  Besides the assessment of whether the blocking patent can be successfully challenged, a number of variables appear generally relevant to the calculus, including: the costliness of the project; the risk of research failure; the nature of improvements that might arise from the project, and whether such improvements will be entirely covered by the blocking patent; the size of the market opportunities anticipated for such improvements; the costs of arriving at the improvements and getting them to market; the risk of losing the invention race to a blocking-patent owner or licensee; the risk that the blocking-patent owner (making its own economic calculations, perhaps in light of its own other products or research activities) will altogether refuse to grant a license to the improvement or will demand so large a share of profits that the whole project is not worthwhile for the potential innovator—all evaluated in light of other investment opportunities.

    Taking these factors and the prior art into consideration (including the fact that Acorda been given an exclusive license to Elan's patent), the majority held that the District Court had not erred in its analysis, a conclusion supported by the deference due the District Court on the factual question of commercial success.  The same blocking effect was also fatal (to the panel majority) to the assertion of "long-felt need" and "failure of others" as objective indicia of non-obviousness.

    Not so for Judge Newman, whose dissent (in comparison to the majority) illustrates the pitfalls that exist in any obviousness determination.  Judge Newman considers the exact same prior art and evidence that convinced the majority, and it convinces her of their error.  To Judge Newman, the history of the prior art was one of failure of many others to achieve the claimed invention.  And to Judge Newman the "new legal theory" regarding the almost plenary effect of "blocking patents" on the objective indicia is not just inimical to the patentee but to "the afflicted public," who would have lost the opportunity for Ampyra® to have been developed if, in prescient retrospect Acorda had foreseen the majority's outcome.  Judge Newman cites the prior art as showing "decades of failure" to wrestle this unwieldy drug, with its "narrow toxic-to-therapeutic range[]" associated with unpredictable and severe side-effects, to the reliable therapeutic uses achieved by Acorda:

    The record shows that many scientists in many institutions studied and eventually abandoned 4-AP as a treatment prospect for multiple sclerosis.  These abandoned studies constitute the prior art on which the district court and my colleagues rely for obviousness of the Acorda Patents. However, the experimentation with 4-AP shows just the opposite – it shows that work with 4-AP was abandoned due to the inability to balance the compound's potential effectiveness with its toxicity.

    Over and over, through her litany of the prior art, she shows that the majority used prior art to support obviousness that revealed failure to achieve the therapeutic goals without risking (and incurring) serious side effects.  Judge Newman sets forth instances where the majority apparently ignored or downplayed evidence that prior art upon which their decision relied reported abandonment of research and development efforts on 4-AP due to "toxicity and seizures," encephalopathy, and hepatitis, or "dizziness, hypotension, or nausea" that accompanied the drug's use.  The record shows that even Acorda, like all the other researchers, initially failed to develop a sustained release formulation and administration regimen effective in improving walking speed in MS patients, and that it was only when Acorda achieved an "analytical breakthrough" (i.e., a reevaluation of the clinical data) that its Ampyra® product was successfully developed.

    In addition, with regard to the majority's base determination of obviousness, Judge Newman asserts that "the question is not whether these four elements [as set forth above], if combined, would produce a successful treatment.  The question is whether the prior art contains a suggestion or motivation to select these four elements from the decades of inconclusive prior art, with a reasonable expectation that the selection would eliminate the failures of the prior art," citing In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig., 676 F.3d 1063, 1068–69 (Fed. Cir. 2012).  For Judge Newman, "[t]he years of studies and failures weigh heavily against the simplistic post hoc predictability accepted by the court."  Judge Newman finds no basis for the majority's determination that the skilled worker would have had a reasoned basis from the art to make the selections Acorda did nor any reasonable expectation of success if the skilled worker had done so:

    Acorda is correct that there was no suggestion in the prior art that the claimed combination should be tried, and there is no hint of a reasonable expectation of success.  Acorda points to the decades of failure of others to develop a safe and effective treatment for multiple sclerosis using 4-AP, despite its known toxicity.  The district court's selection of separate limitations from separate sources, and retrospectively fitting them into the Acorda template, is achieved only with the hindsight knowledge of Acorda's eventual success.  See Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075, 1086 (Fed. Cir. 2008) ("The determination of obviousness is made with respect to the subject matter as a whole, not separate pieces of the claim.").  Here, only the Acorda Patents teach the combination that successfully treats this multiple sclerosis impairment while avoiding toxicity and seizures.

    And with regard to commercial success, Judge Newman's analysis provides a compelling argument that the District Court and the majority made the wrong comparison in deciding that Elan's "blocking patent" was relevant to the question:

    Commercial success is measured against the products available for the same purpose, not against infringing copies of the patented product.  Defendants do not contend that they are precluded from providing or developing other treatments for multiple sclerosis.  The Acorda product met a long-felt need, for which the failure of others, despite decades of experimenting with the neurological properties of 4-AP, is evidence of the unobviousness of the Acorda achievement.  Such evidence is an important aid to a court that is attempting to divine whether the patentee's discovery was obvious in accordance with law [emphasis added].

    For good measure, Judge Newman ends her dissent by noting that "[t]he district court was advised that the Patent Trial and Appeal Board sustained the validity of the Acorda Patents in inter partes review, at Coalition for Affordable Drugs (ADROCA), LLC v. Acorda Therapeutics, Inc., 2017 WL 950736 (P.T.A.B. Mar. 9, 2017).  Although the majority reports this event, as did the district court, its consequences are not explored, including issues of privity, estoppel, and finality."

    Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc. (Fed. Cir. 2018)
    Panel: Circuit Judges Newman, Dyk, and Taranto
    Opinion by Circuit Judge Taranto; dissenting opinion by Circuit Judge Newman

  • Claim for Scheduling Packet Data Communication Survives Patent Eligibility Challenge in Motion to Dismiss

    By James Korenchan —

    Last week, in yet another patent case before Judge Rodney Gilstrap of the U.S. District Court for the Eastern District of Texas Marshall Division, the Court ruled that Defendants T Mobile USA, Inc. and T-Mobile US, Inc. (collectively, "T-Mobile") failed to show that a claim related to packet scheduling is patent ineligible under 35 U.S.C. § 101.

    T-Mobile had moved to dismiss claim 109 of U.S. Patent. No. RE46,206 (the '206 patent) (a reissue of U.S. Patent No. 7,251,218) as directed to ineligible subject matter.  In addition, T-Mobile, as well as Defendants Ericsson Inc. and Telefonaktiebolaget LM Ericsson, moved to dismiss all claims of U.S. Patent No. 7,359,971 and claim 1 of the '206 patent as barred by issue preclusion.  The Court carried the motion under issue preclusion grounds but denied the motion as to patent eligibility.

    The '206 patent relates generally to packet data communication based on end-user quality of service (QoS) requirements.  As described in the Background of the patent, packet switching — which breaks up network data traffic into "packets" for transmission from one device to another device for reassembly — uses available wireless network bandwidth more efficiently than circuit switching in that it enables many devices to share the available bandwidth.  The invention of claim 109 takes end-user QoS requirements into account when scheduling packet data to be transmitted over a shared bandwidth.  In particular, packets are classified according to such QoS requirements and then scheduled for upstream and downstream communication "according to a scheduling algorithm."

    For reference, claim 109 is provided below:

    109.  A method for scheduling packets comprising:
        classifying a plurality of packets according to end-user quality of service (QoS) requirements of said plurality of packets; and
        scheduling said plurality of packets for communication in at least one of an upstream direction and a downstream direction over a shared wireless bandwidth according to a scheduling algorithm.

    In their motion to dismiss, T-Mobile not only argued that claim 109 is directed to the abstract idea of "classifying information based on an end-user's service requirements and scheduling information," but that the claim is "so abstract" that it can be performed by the human mind or using pen and paper.  T-Mobile even provided a drawing to illustrate this point (complete with a hand holding a pencil, to drive the point home even further):

    FigureIn addition, T-Mobile analogized claim 109 to classifying mail according to customer service requirements and scheduling mail (similar to an analogy made in Intellectual Ventures I LLC v. Symantec Corp., which T-Mobile cited for support).  T-Mobile also cited to Federal Circuit decisions in Cyberfone Sys., LLC v. CNN Interactive Grp., Inc. and In re TLI Commc'ns LLC Patent Litig., the former of which found an abstract idea in "collecting information in classified form, then separating and transmitting that information in classified form," and the latter of which found an abstract idea in "classifying and storing digital images in an organized manner."  Emphasizing In re TLI, T-Mobile asserted that the concept of storing digital images could be substituted for scheduling information.

    In response, Intellectual Ventures argued that T-Mobile trivialized the invention and described the claims at too high a level.  Intellectual Ventures also argued that the invention makes little sense outside of the context of telecommunications, and overcomes a problem specifically arising in that realm — namely, that "different types of data packets have different ideal quality of service ("QoS") settings, which results in suboptimal data flow when, for example, voice packets and data packets are transferred over the same connection."  According to Intellectual Ventures, claim 109 specifically addresses this problem by requiring wireless networks to classify packets according to QoS requirements before scheduling the packets for communication.

    The Court agreed that "[the] '206 patent is directed to a technical solution to a technical problem" and was persuaded that the patent sufficiently describes the invention as such.  In particular, the Court cited to portions of the patent that discuss existing challenges that wireless networks face in delivering QoS to end-users, including network congestion.  The Court then elaborated:

    The '206 Patent is explicit in its solution to these problems.  Indeed, the first sentence, covering the field of the invention, states "The present invention relates generally to telecommunications and, more particularly, to a system and method for implementing a QoS aware wireless point-to-multi-point transmission system."  (emphasis added).  The "Summary of the Invention" states that "[t]he present invention is directed to an IP flow classification system used in a wireless telecommunications system.  More specifically, the IP flow classification system groups IP flows in a packet-centric wireless point to multi-point telecommunications system."  Accordingly, the '206 Patent makes clear that the patented invention is directed towards a technological solution to these stated problems.  Such solution is achieved by classifying, on a packet level, what the ideal quality of services characteristics are for each type of data in order to optimize data flow.  Under Rule 12(b)(6), the Court is required to take these affirmative statements as true.

    (citations omitted).

    The Court thus found that the '206 patent is directed to patent eligible subject matter and that the Defendants failed to show otherwise.

    Intellectual Ventures I LLC v. T Mobile USA, Inc. (E.D. Tex. 2018)
    Order Carrying-in-part and Denying-in-part Defendant's Motion to Dismiss by District Judge Gilstrap

  • Federal Circuit Affirms PTAB in Appeal of CRISPR Interference

    By Kevin E. Noonan —

    Federal Circuit SealBarring the unlikely event that the Federal Circuit rehears en banc today's decision in Regents of the University of California v. Broad Institute, Inc. (or, even more unlikely, that the Supreme Court grants certiorari), the interference between the Broad Institute and the University of California/Berkeley is now concluded.  The Court affirmed the Patent Trial and Appeal Board's decision (see "PTAB Decides CRISPR Interference — No interference-in-fact"; "PTAB Decides CRISPR Interference in Favor of Broad Institute — Their Reasoning") that there is no interference-in-fact between the Broad's twelve patents (the Federal Circuit citing U.S. Patent No. 8,697,359 as being representative) and one application-in-interference and the University of California/Berkeley's pending application (Application No. 13/842,859).

    To recap, the Board found that there was no interference-in-fact based on these requirements:

    In this proceeding, to prevail on its argument that there is no interference, Broad must show that the parties' claims do not meet at least one of the following two conditions:

    1) that, if considered to be prior art to UC's claims, Broad's involved claims would not anticipate or render obvious UC's involved claims, or

    2) that, if considered to be prior art to Broad's claims, UC's involved claims would not anticipate or render obvious Broad's claims.

    Broad will prevail and a determination of no interference-in-fact will be made if a preponderance of the evidence indicates one of these conditions is not met.

    In considering the evidence before it, the PTAB gave great weight to contemporaneous, cautious statements in the art in view of Professor Doudna's disclosure of in vitro CRISPR activity regarding whether the system would work in eukaryotic cells.  Specifically, these statements convinced the Board that while the results "suggested the 'exciting possibility'" that CRISPR-Cas9 could be operative in eukaryotic cells, "it was not known whether such a bacterial system would function in eukaryotic cells."  And "[i]n another report, Doudna was quoted as stating that she had experienced 'many frustrations' getting CRISPR to work in human cells and that she knew that if she succeeded, CRISPR would be 'a profound discovery.'"  UC's assertion of other statements by their inventors that could be interpreted more positively did not convince the Board that there was a reasonable expectation of success in the art for getting the CRISPR-Cas9 system to work in eukaryotic cells, the Board stating that:

    Although the statements express an eagerness to learn the results of experiments in eukaryotic cells and the importance of such results, none of them express an expectation that such results would be successful.

    The Board swept aside Berkeley's arguments that this reasoning was flawed because the standard is not the inventor's expectations but those of the worker of ordinary skill by stating that "if the inventors themselves were uncertain, it seems that ordinarily skilled artisans would have been even more uncertain."  The Board also quoted Berkeley's expert as having said (contemporaneously with Professor Doudna's report of in vitro CRISPR activity):

    There is no guarantee that Cas9 will work effectively on a chromatin target or that the required DNA-RNA hybrid can be stabilized in that context.

    The Board concluded that "[w]e fail to see how 'no guarantee' indicates an expectation of success."

    Nor was the Board convinced based on the history of the development of CRISPR technology, which showed that many laboratories independent of the Doudna group quickly applied the new technology to manipulate eukaryotic cell genomic DNA:

    Regardless of how many groups achieved success in eukaryotic cells, we are not persuaded that such success indicates there was an expectation of success before the results from these experiments were known.  The unpublished results of research groups are not necessarily an indication of whether ordinarily skilled artisans would have expected the results achieved.  Instead of viewing such work as evidence of an expectation of success, we consider the number of groups who attempted to use CRISPR-Cas9 in eukaryotic cells to be evidence of the motivation to do so, an issue that is not in dispute.  We agree with Broad's argument that a large reward might motivate persons to try an experiment even if the likelihood of success is very low.

    On balance, the Board found that this evidence further supported their decision that there was insufficient evidence of a reasonable expectation of success to support Berkeley's allegation that their earlier work and publications would have rendered Broad's invention obvious.  This evidence was that "differences in gene expression, protein folding, cellular compartmentalization, chromatin structure, cellular nucleases, intracellular temperature, intracellular ion concentrations, intracellular pH, and the types of molecules in prokaryotic versus eukaryotic cells, would contribute to this unpredictability [regarding whether the CRISPR-Cas9 system would be operative in eukaryotic cells]."  In response to Berkeley's allegations that these considerations turned out not to be an impediment to CRISPR's activity in eukaryotic cells, the Board said "[t]he relevant question before us is whether those of skill in the art would have expected there to be problems before the experiments were done," not whether it turned out that the experiments were successful once they were tried.

    Finally, the Board rejected Berkeley's citation of other prokaryotic genetic modification systems found to work in eukaryotes, generally on the grounds that there was no "commonality" in these methods that would have refuted Broad's evidence that the skilled worker would not have had any reasonable expectation of success.

    The University appealed, and today the Federal Circuit affirmed, in an opinion by Judge Moore joined by Chief Judge Prost and Judge Schall.  After a recitation of a description of CRISPR (see "CRISPR Interference Declared" for a description of this technology) and the substantive and procedural posture before the PTAB, the Court addressed the legal arguments proffered by California in support of its argument against the PTAB's decision of no interference-in-fact.  As stated in the opinion,

    The case turns in its entirety on the substantial evidence standard.  The Board found a person of ordinary skill in the art would not have had a reasonable expectation of success in applying the CRISPR-Cas9 system in eukaryotic cells.  . . .  Given the mixture of evidence in the record, we hold that substantial evidence supports the Board's finding that there was not a reasonable expectation of success, and we affirm.

    The opinion then addressed California's two arguments contrary to the PTAB's decision:  "that the Board: (1) improperly adopted a rigid test for obviousness that required the prior art contain specific instructions, and (2) erred in dismissing evidence of simultaneous invention as irrelevant."  The Court based its opinion on the evidence presented by one of the Broad's experts with regard to the difference between prokaryotic and eukaryotic cells (which it recited extensively) "that rendered the application of the CRISPR-Cas9 system in eukaryotic cells unpredictable."  The issues these differences raised relevant to whether the skilled worker would have had a reasonable expectation of success in applying CRISPR to eukaryotic cells were also, according to the opinion, recognized by California's expert, including inter alia statements like "[t]here is no guarantee that Cas9 will work effectively on a chromatin target or that the required DNA-RNA hybrid can be stabilized in that context" and "whether the CRISPR-Cas9 system will work in eukaryotes 'remains to be seen' and '[o]nly attempts to apply the system in eukaryotes will address these concerns.'"  This evidence was supported, in the panels' opinion, from California's own inventors (including Jennifer Doudna) "acknowledging doubts and frustrations about engineering CRISPR-Cas9 systems to function in eukaryotic cells and noting the significance of Broad's success."  In addition, the Court noted evidence that other prokaryotic systems adapted to eukaryotic cells ("riboswitches, ribozyme systems, and group II introns") "either [had] limited efficacy or the technology required a specific strategy to adapt it for use in eukaryotic cells."  This evidence amounted to substantial evidence that the skilled worker would not have had a reasonable expectation of success in achieving CRISPR in eukaryotic cells.

    (The opinion recognizes that California had presented evidence in support of its position, but noted "[w]e are, however, an appellate body.  We do not reweigh the evidence.  It is not our role to ask whether substantial evidence supports fact-findings not made by the Board, but instead whether such evidence supports the findings that were in fact made.")

    The opinion also rejected California's arguments that the Board had used a rigid test that required specific instructions in the prior art and ignored the "inferences and creative steps" recognized as being relevant to an obviousness determination under the Supreme Court's decision in KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 418, 420 (2007).  And with regard to "simultaneous invention" evidence (which California argues the Board ignored), the opinion states that while "[s]imultaneous invention may serve as evidence of obviousness when considered in light of all of the circumstances," citing Lindemann Maschinenfabrik GmbH v. Am. Hoist & Derrick Co., 730 F.2d 1452, 1460 (Fed. Cir. 1984), the existence of interferences means that simultaneous invention cannot, by itself, be evidence of obviousness.  The Federal Circuit rejected California's argument that evidence that six independent research groups applied CRISPR to eukaryotic cells "within a short period of time" after publication of Its discovery on prokaryotes rendered the Broad's claims obvious, and approved the legal rationale used by the PTAB:

    The Board explained that "[e]ach case must be decided in its particular context, including the characteristics of the science or technology, its state of advance, the nature of the known choices, the specificity or generality of the prior art, and the predictability of results in the area of interest."  . . . (quoting Abbott Labs. v. Sandoz, Inc., 544 F.3d 1341, 1352 (Fed. Cir. 2008)).  We do not see any error in this analysis.

    The consequence of this decision (assuming it is the final word) is that the status quo will remain:  the Broad will maintain its extensive CRISPR patent portfolio and the University's patent application (reciting claims broader than the Broad's and encompassing CRISPR without regard to the cells in which it is practiced) should grant as a patent in due course.  Under these circumstances, a third party wishing to practice the technology in eukaryotic cells (encompassing everything from yeast to man) would need a license from both the University and the Broad (absent the parties coming to an agreement on how their overlapping technologies will be licensed).  This circumstance cannot fail to retard commercial adoption of the techniques, providing further impetus for some sort of co-licensing agreement between the parties to be forged.

    Regents of the University of California v. Broad Institute, Inc. (Fed. Cir. 2018)
    Panel: Chief Judge Prost and Circuit Judges Schall and Moore
    Opinion by Circuit Judge Moore

  • By Bryan Helwig —

    USPTO SealAbout the PTAB Life Sciences Report:  We will periodically report on developments at the PTAB involving life sciences patents.

    Par Pharmaceutical, Inc. v. Horizon Therapeutics, LLC

    PTAB Petition:  IPR2018-01550; filed August 21, 2018.  View Petition here.

    Patent at Issue:  U.S. Patent No. 9,561,197, "Methods of therapeutic monitoring of phenylacetic acid prodrug" describes methods of treating a nitrogen retention disorder by measuring a subject's plasma phenylacetic acid ("PAA") and phenylacetylglutamine ("PAGN") levels, and determining whether the dosage of a nitrogen scavenging drug needs to be adjusted based on whether the plasma PAA:PAGN ratio falls within a target range.

    Background:  Petitioner requests institution of inter partes review, seeking cancellation of claims 1 and 2 of the '197 patent as unpatentable under 35 U.S.C. § 103(a).  Petitioner alleges that the challenged claims merely apply known techniques to a known method of using glyceryl tri-[4-phenylbutyrate] (GPB) to treat urea cycle disorders.  Petitioner notes that in patients with urea cycle disorders, the clinical benefit of GPB derives from the ability of GPB to metabolize into PAA1, which conjugates with nitrogen to form PAGN and replace urea as a vehicle for carrying waste nitrogen out of the body.  This conjugation avoids the buildup of toxic ammonia in patients with defective urea cycle functionality.  Petitioner notes that the challenged claims generally recite methods of administering a dose of GPB in an amount effective to achieve a specific ratio of PAA to PAGN in the subject's plasma, in subjects whose PAA:PAGN plasma ratio is outside a specific range.


    Becton, Dickinson and Company v. bioMérieux SA

    PTAB Petition:  IPR2018-01566; filed August 21, 2018.  View Petition here.

    Patent at Issue:  U.S. Patent No. 8,367,337, "Detection of methicillin-resistant Staphylococcus aureus" is directed at improved tests for the detection of methicillin-resistant Staphylococcus aureus.  The patent provides a method of detecting in a sample a methicillin-resistant Staphylococcus aureus (MRSA) having an insertion of a SCCmec cassette within Staphylococcus aureus chromosomal DNA.  The patent claims methods for an amplification and detection reaction utilizing a first and second primer and a probe that hybridizes when a sample contains MRSA.

    Background:  Petitioner challenges claims 15 and 29-31 of the '337 patent and requested institution of inter partes review.  The claims are directed to methods of detecting methicillin-resistant Staphylococcus aureus (MRSA), a deadly antibiotic-resistant bacteria strain.  Petitioner alleges that the claimed methods utilize the known technique of multiplex DNA amplification to detect the presence or absence of two distinct DNA segments of the MRSA genome: (1) the junction between two pieces of DNA found in the MRSA genome, referred to herein as the "SCCmec junction" and (2) a region of the methicillin resistance gene, the mecA gene, wherein the presence of both DNA segments in a sample confirms that MRSA is present in the sample.  Petitioner further asserts that an important prior art reference was not of record during prosecution.


    Grunenthal GmbH v. Antecip Bioventures II LLC

    PTAB Petition:  PGR2018-00092; filed August 21, 2018.  View Petition here.

    Patent at Issue:  U.S. Patent No. 9,820,999, "Neridronic acid for treating complex regional pain syndrome" is directed at osteoclast inhibitors, such as neridronic acid, in an acid or salt form that can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

    Background:  The '999 patent covers methods of treating pain associated with complex regional pain syndrome (CRPS).  Petitioner alleges that before any of the '999 patent's priority applications were filed, it was well-known that bisphosphonate drugs, like neridronic acid, could be used to treat pain associated with CRPS.  Petitioner claims that because of this knowledge, the patent owner directed the '999 patent claims to effective treatment of pain associated with CRPS specifically triggered by fracture.  Petitioner further alleges that the use of neridronic acid to treat pain associated with CRPS triggered by fracture was already known in the art.  Petitioner states that data that Patent Owner used to purportedly support the '999 patent and its parent's claims allegedly came from a much earlier randomized, double-blind, placebo-controlled clinical trial published in 2012.  As a result, Petitioner requests post grant review and cancellation of '999 patent claims 1-30 as unpatentable under 35 U.S.C. §§ 112, 102, and/or 103.

    Related Matters:
    • Petitioner filed PGR against U.S. Patent No. 9,283,239, "Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome" on December 14, 2016 (PGR2017-00008).
    • Petitioner filed PGR against U.S. Patent No. 9,408,862, "Therapeutic compositions comprising imidazole and imidazolium compounds" on May 8, 2017 (PGR2017-00022).
    • Petitioner filed PGR against U.S. Patent No. 9,539,268, "Therapeutic compositions comprising imidazole and imidazolium compounds" on October 10, 2017 (PGR2018-00001).
    • Petitioner filed a PGR against U.S. Patent No. 9,707,245, "Neridronic acid for treating complex regional pain syndrome" on April 18, 2018 (PGR2018-00062).
    • The '999, '245, and '239 patents are all part of the same patent family.  Post-grant review was instituted against the ′239 patent.  The Board issued a final written decision finding all challenged claims unpatentable for lack of written description.  An institution decision is forthcoming in PGR2018-00062, against the '245 patent.
    • The '862 and '268 patents belong to a different patent family than the '999 patent, but share the same inventor and also cover methods of treating pain conditions with bisphosphonate drugs.  Post grant review was instituted against the '862 patent and the Board heard oral arguments on July 24, 2018.  Post grant review was instituted against the '268 patent PGR2018-00001 in May 2018.


    Luitpold Pharmaceuticals, Inc. v. Apicore US LLC

    PTAB Petition:  IPR2018-01640; filed August 31, 2018.  View Petition here.

    Patent at Issue:  U.S. Patent No. 9,353,050, "A process for the preparation of isosulfan blue" describes a process for preparation of an active pharmaceutical ingredient.  A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula, used in the preparation thereof and a procedure for the isolation of benzaldehyde-2,5-disulfonic acid, di-sodium salt of the formula.  Also provided is a process for the preparation of an isoleuco acid of formula, which upon mild oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations.

    Background:  Petitioner seeks IPR against claims 1–18 of the '050 patent as unpatentable.  Petitioner claims that an isosulfan blue sodium salt ("ISB") product was FDA-approved and in pharmaceutical use since the early 1980s, long before the priority date of the '050 patent.  Petitioner claims that the only allegedly novel aspect of the challenged claims is the purity level and claims that no secondary considerations outweigh obviousness.

  • CalendarSeptember 11, 2018 – "How Notre Dame's IDEA Center Took University Start-Up Formation from Puny to Powerhouse: A Case Study in Performance Improvement" (Technology Transfer Tactics) – 1:00 pm to 2:00 pm (ET)

    September 12, 2018 – "Evolving PTAB Trial Practice: Navigating Complex Procedural Rules — Strategically Using Routine and Additional Discovery, Requests for Joinder, and Motions to Amend" (Strafford) – 1:00 to 2:30 pm (EDT)

    September 13, 2018 – "Blockchain and IP: Navigating Emerging Issues — Blockchain, DLT Platforms, Crypto-Tokens, Smart Contracts, and More" (Strafford) – 1:00 to 2:30 pm (EDT)

    September 13, 2018 – "The Revised PTAB Trial Practice Guide and Its Impact on Your Practice" (The Intellectual Property Owners Association) -  2:00 to 3:00 pm (ET)

    September 14, 2018 – "Trade Secrets: What Every IP Attorney and In-house Counsel Should Know" (John Marshall Law School Center for Intellectual Property, Information & Privacy Law ) – 9:00 am to 4:30 pm, Chicago, IL

    September 18, 2018 – "The Continued Influence of PTAB Proceedings on Bio/Pharma Patents" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    September 18, 2018 – "3D Printing: Implications for Patents, Trademarks, Trade Secrets and Copyrights — Challenges With Additive Manufacturing, Policing and Enforcement Strategies to Protect IP" (Strafford) – 1:00 to 2:30 pm (EDT)

    September 21, 2018 – "USPTO Post-Grant Patent Trials 2018: Change & Recalibration" (Practising Law Institute) – New York & Groupcasts in Philadelphia, Indianapolis, New Brunswick, NJ, Pittsburgh, and Mechanicsburg, PA

    September 23-25, 2018 – Annual Meeting (Intellectual Property Owners Association) – Chicago, IL

    September 24, 2018 – Biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting (U.S. Patent and Trademark Office) – Alexandria, VA

    September 26, 2018 – "IP Audit Checklist: Best Practices to Identify, Protect, Monetize and Enforce University IP Assets" (Technology Transfer Tactics) – 1:00 pm to 2:00 pm (ET)

    September 27-28, 2018 – "Advanced Patent Prosecution Workshop 2018: Claim Drafting & Amendment Writing" (Practising Law Institute) – Chicago, IL

    September 27-28, 2018 – FDA Boot Camp (American Conference Institute) – Boston, MA

    October 2, 2018 – "Advice of Counsel Defense in Patent Litigation and Protecting Attorney-Client Privilege — Limiting Scope of Discovery, Safeguarding Confidential Communications and Information" (Strafford) – 1:00 to 2:30 pm (EDT)

    October 2-3, 2018 – Paragraph IV Disputes master symposium (American Conference Institute) – Chicago, IL

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "The Revised PTAB Trial Practice Guide and Its Impact on Your Practice" on September 13, 2018 from 2:00 to 3:00 pm (ET).  Hon. Michael Tierney, Lead Administrative Patent Judge, Patent Trial and Appeal Board, U.S. Patent and Trademark Office; Tarek Fahmi of Ascenda Law Group; and Eliot Williams of Baker Botts LLP will discuss the reasoning behind recent changes to the PTAB Trial Practice Guide and explain how these revisions will impact PTAB practice.  Among the major revisions to the Guide that will be addressed, are:

    • The introduction of a sur­reply to
the prior sequence of briefs
    • The circumscribed role to be played by expert evidence
    • The introduction of a new prehearing conference call, which some commentators predict has the potential to be as important as the main oral hearing
    • Clarifications regarding motions to strike and motions to exclude

    The registration fee for the webinar is $135 (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.

  • USPTO Building FacadeThe U.S. Patent and Trademark Office will be holding its next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting on September 24, 2018 at the USPTO Headquarters (Alexandria, VA).  The agenda for the meeting is as follows:

    • Welcoming and Opening Remarks (10:00 – 10:10 am EDT) – Gary Jones, Daniel Sullivan, and Andrew Wang, Directors, TC1600, USPTO

    • Obviousness of Biologics: Identifying the Biggest Challenges (10:10 – 11:00 am) — Carla Mouta-Bellum of Arrigo, Lee, Guttman & Mouta-Bellum LLP

    • Exemplary Obviousness Rationales Suggested in KSR (11:00 – 11:50 am) — Lora Driscoll, QAS, TC1600, USPTO

    • Lunch (11:50 am – 12:50 pm)

    • 112(f)-New Form Paragraphs (12:50 – 1:40 pm) — Marjorie Moran, QAS, TC1600, USPTO

    • Requirements for Information Under 37 CFR 1.105 and Responses to Said Requirements (1:40 – 2:40 pm) — Amjad Abraham, SPE, and Shubo (Joe) Zhou, SPE, TC1600, USPTO

    • Break (2:40 – 3:00 pm)

    • Accidental Infringement: the need for additional limitations in plant utility claims directed to chemical profiles or cultivars (3:00 – 3:50 pm) — Reggie Gaudino, Chief Science Officer, Steep Hill Labs, Inc.

    • Closing Remarks (3:50 – 4:00 pm) – Directors, TC1600, USPTO

    Additional information regarding the BCP customer partnership meeting, including registration information for those wishing to attend the meeting or register for online participation, can be found here.

  • IPO Brochure CoverThe Intellectual Property Owners Association (IPO) will be holding its 46th Annual Meeting on September 23-25, 2018 in Chicago, IL.  Among the presentations being offered at the annual meeting are:

    • A Year in Review: Patent Case Law Update
    • AIA Estoppel: A New Flavor of Collateral Estoppel and/or Res Judicata?
    • The Intersection of IP and Open Source
    • Navigating the E-Discovery Minefield; International Litigation and Availability of Discovery Under 28 U.S.C. §1782
    • Business Methods (computer implemented inventions) Workshop
    • The Supreme AIA Update: A Triple-Header
    • The Practice of IP Law in the Age of Machine Learning, Knowledge Management, and Blockchain
    • Protecting Your Trade Secrets in Todays' Global Village
    • How Corporations Hedge Against Emerging Technology
    • Protecting Software in the Pharmaceutical and Health Care Industries
    • Global Dossier
    • Strategies for Addressing Gender Disparity in Patenting
    • Managing Risks of Willful Infringement: Practical Considerations and Guidelines
    • Attorney-Client Privilege: Considerations for General Communications and Communications During Patent Preparation and Prosecution
    • Time to Call 911 (Emergency!) on 101: Is Patent Eligibility Doctrine Undermining U.S. Leadership in Innovation?
    • Finding Common Ground: Best Practices for Efficiently Prosecuting Patent Applications at the USPTO
    • Portfolio Management: Strategy and Value Behind IP Audits
    • Ethics Session: Conflicts of Interest

    In addition, Andrei Iancu, Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office will present a keynote address on September 24, and Hon. Kathleen O'Malley, Circuit Judge, U.S. Court of Appeals for the Federal Circuit will present a keynote address on September 25.

    A program for the meeting, including an agenda, descriptions of the scheduled sessions, and list of speakers, can be obtained here.

    The registration fee for the meeting is $500 (government/academic), $995 (IPO members), or $1,675 (non-members).  Those interested in registering for the meeting can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "3D Printing: Implications for Patents, Trademarks, Trade Secrets and Copyrights — Challenges With Additive Manufacturing, Policing and Enforcement Strategies to Protect IP" on September 18, 2018 from 1:00 to 2:30 pm (EDT).  Elizabeth D. Ferrill of Finnegan Henderson Farabow Garrett & Dunner, Christopher Higgins of Orrick Herrington & Sutcliffe, and Marc H. Trachtenberg of Greenberg Traurig will examine 3D printing and its current and potential implications for patents, trademark, trade dress, trade secret, and copyrights, and offer guidance for developing enforcement strategies to police and protect IP rights in the emerging world of additive manufacturing.  The webinar will review the following issues:

    • How does 3D printing of products impact different types of intellectual property?
    • When determining which type of protection to seek, what factors related to 3D printing should IP counsel consider?
    • What steps should counsel take to police and protect IP in light of 3D printing?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.